After 30 years of trading on Nasdaq, Teva Pharmaceutical Industries is thinking of moving to the New York Stock Exchange. The move is probably the brainchild of Teva chairman Phillip Frost, who is associated with the NYSE and has reportedly been pitching the idea to incoming CEO Jeremy Levin, say industry insiders. In April 2005 Frost was named vice-chairman of the AMEX exchange, which the NYSE acquired in 2008. He has controlling interests in a number of NYSE-listed companies, including Ivax Corp (which Teva acquired ), biomed company Prolor, financial services company Ladenberg, alcoholic beverages maker Castle, and the pharma company Opko.
